Black Lion Research Rebirth
Black Lion Research Rebirth Introducing Black Lion Research Rebirth the first natural SERM that you can count on to deliver results. Rebirth can be used to mitigate Gyno by blocking the estrogen receptor and not allowing it to be bound to. Also it is very applicable in the PCT Period to kickstart your HPTA to start your own production back ASAP. Combine Rebirth with a Aromatase Inhibitor and your PCT is set. With absorption enhancers this product will deliver shocking results.Ellagic Acid is a plant-derived polyphenol, possessing antioxidant, antiproliferative, and antiatherogenic properties. Whether this compound has estrogenic/antiestrogenic activity, however, remains largely unknown. To answer this question, we first investigated the ability of ellagic acid to influence the activity of the estrogen receptor subtypes ERalpha and ERbeta in HeLa cells. Cells co-transfected with an estrogen response element (ERE)-driven luciferase (Luc) reporter gene and an ERalpha- or ERbeta-expression vector were exposed to graded concentrations of ellagic acid. At low concentrations (10(-7) to 10(-9) M), this compound displayed a small but significant estrogenic activity via ERalpha, whereas it was a complete estrogen antagonist via ERbeta. Further evaluation revealed that ellagic acid was a potent antiestrogen in MCF-7 breast cancer-derived cells, increasing, like the pure estrogen antagonist ICI182780, IGFBP-3 levels. Moreover, ellagic acid induced nodule mineralization in an osteoblastic cell line (KS483), an effect that was abolished by the estrogen antagonist. Endometrium-derived epithelial cells (Ishikawa) showed no response to the natural compound by using a cell viability assay (MTT). These findings suggest that ellagic acid may be a natural selective estrogen receptor modulator (SERM).
- [PubMed – indexed for MEDLINE]
The edible red seaweed Eucheuma cottonii is abundantly cultivated for carrageenan production. This study investigated the effects of dietary E. cottonii polyphenol-rich extract (ECME) on breast cancer. In vitro assays showed that ECME was antiproliferative against oestrogen-dependent MCF-7 and oestrogen-independent MB-MDA-231 human breast-cancer cells (IC50 values of 20 and 42 μg/ml, respectively) but was non-toxic to normal cell lines. The ECME (150 and 300 mg/kg BW) was fed to female rats and, after 4 weeks, rat mammary tumour was induced using LA7 cells (inoculated subcutaneously). The ECME inhibited tumour development and erythrocyte lipid peroxidation in the cancer-induced rats, dose-dependently. It showed anti-oestrogenic effects on the rat estrous cycle and serum hormone levels. Electron microscopy and histopathology observations confirmed apoptosis in the rat mammary tumours. The polyphenol-rich ECME was tumour-suppressive via apoptosis induction, downregulating the endogenous oestrogen biosynthesis, and improving antioxidative status in the rats.
Apoptotic effects in oestrogen dependent and independent human breast cancer cells. The anti-estrogenic properties in female mammals. Breast tumour prevention and suppression using sustainable cultivated seaweeds.
|Serving Size: 1 Capsule|
|Servings per container: 60|
|Amount per serving||%DV|
|Ellagic Acid Cyclodextrin Complex||400mg||**|
|**(DV)Daily Value Not Established|
Other Ingredients: Cellulose, Magnesium Stearate, Blue#1